Affectis Pharmaceuticals AG Granted Patent for AFC-5128, Other P2X7 Antagonists
1/25/2012 9:15:39 AM
More...
|
Affectis Pharmaceuticals AG and Merck Serono Announce an Agreement to Develop Oral Drugs for Neurodegenerative Diseases
6/8/2011 9:28:50 AM
More...
|
Affectis Pharmaceuticals AG Names Stephen Murray, MD, PhD, as Chief Medical Officer
5/5/2010 11:33:39 AM
More...
|